Phase 3 | Metastatic urothelial cancer | HER2-expressing
Target 520 patients. 1 US site live. Registered Oct 13.
Why it matters: site expansion and HER2 testing ahead.
Good for: site networks, recruitment, specialty labs.
Sponsor: emerging biotech
For clinical research sales teams
Pharma Pulse sends your team new US oncology studies, new investigator sites and enrollment changes every week, each tagged with why it matters to what you sell.
Sample leads
Three real leads from this week's feed. Sponsor names are held back here; subscribers get the sponsor, study and every listed site.
Target 520 patients. 1 US site live. Registered Oct 13.
Why it matters: site expansion and HER2 testing ahead.
Good for: site networks, recruitment, specialty labs.
Sponsor: emerging biotech
Target 1,330 patients. 42 US sites in 20 states: 3 enrolling, 37 not yet enrolling, 2 dropped out.
Why it matters: 37 US sites switch on in the coming months, and 2 need replacing.
Good for: recruitment, site networks, start-up and feasibility.
Sponsor: top 10 pharma
Target 40 patients. 8 US academic sites named, none enrolling yet. Planned start date has passed.
Why it matters: every site needs radiopharmacy delivery and dosimetry coordination, all at once.
Good for: specialty logistics, site networks.
Sponsor: radiopharma company
Who it's for
Studies where enrollment pain is coming.
New studies that still need US sites, in your states.
Biomarker-selected studies the week they appear.
Emerging biotechs launching their first studies.
Radioligand, cell therapy and ADC studies opening new sites.
How it works
Category, tumor types, phases, states.
New studies, new sites, status and timeline changes, filtered to your fit.
Email plus CSV, ready for your CRM. Each lead says what changed and why it fits you.
Today: US, industry-sponsored, interventional oncology. More therapeutic areas when our customers ask for them.
Pricing
$199/mo
$499/mo
Prefer to talk first? Book a 30-min call or email hello@pharma-pulse.io.
Not sure? Get 5 free leads in your category first. 30 day money back on your first month. Founding pricing locked for our first 10 customers.
FAQ
One study event: a new study, a new site, or a change in enrollment status or timeline, with sponsor, phase, size, sites and a one line reason it fits what you sell.
We give you the sponsor and the sites. Your team uses its own contact tools to reach the right person. That keeps the list accurate and compliant.
Core checks every day. Starter is a weekly roundup.
US industry-sponsored oncology studies. If you need another area, tell us and we will scope it.
Those are research tools priced for sponsors. Pharma Pulse is a sales feed: only what changed, only what fits you, with the reason to call.
Any time, from your billing link. First month is money back if it is not useful.
Public study disclosures and sponsor announcements, checked daily and organized by our own change tracking.
Tell us what you sell, which tumor types and which states. We will send 5 leads that fit, free.
Get 5 free leads in your category